Abstract: A method for the production of crystalline glycopyrronium bromide, comprises the reaction of glycopyrronium base with methyl bromide in a solvent, in which the solvent is selected such that the diastereoisomeric ratio of the product favors the R,S and S,R diastereoisomers over the R,R, and S,S diastereoisomers, and separating the desired diastereoisomers by one or more controlled crystallization steps. This method gives a product having a particle size of narrow distribution.

Abstract: MR imaging and intervention functions are localized within a single device. At least one integrated coil device (62,63,64,90) which has at least one RF coil (72,94,112,118), a housing (70,74,92,96,110,114) which encases the RF coil and provides an anatomically conformal surface, and a plurality of apertures. The integrated coil device slides along a guide rail system (66) to adjust the size of a patient anatomical imaging region (60). The apertures in the integrated coil device are available to secure tool holder grid plate inserts (67,116,130,131) or other interventional device guides. The inserts assist in holding the soft tissue for diagnostic imaging and provide support for biopsy/interventional instrument guides (140). The integrated MR imaging and interventional coil device works in combination with a prone patient support structure (20), an adaptive torso sling (55), and also features an open architecture design for improved patient access. The device also works for supine or side imaging procedures.

Abstract: An energy storage device is provided that includes a separator having a first surface and a second surface. The first surface defines at least a portion of a cathodic chamber, and the second surface defines an anodic chamber. The cathodic chamber includes an alkali metal halide that forms an ion that is capable of conducting through the separator. The anodic chamber has a volume that is filled with a consumable fluid. The amount of the consumable fluid is greater than 90 percent by volume of the anodic chamber volume. Furthermore, the consumable fluid is reactive with an ionic species of the alkali metal halide. A method of sealing the energy storage device is also provided.

Abstract: A cleaning system includes a chassis supporting a propulsion system for propelling the cleaning system across a surface. At least one sensor of a first type is coupled to the chassis, and a surface engagement mechanism is configured to maintain the cleaning system coupled to the surface as the propulsion system propels the cleaning system across the surface. A cleaning device is coupled to the chassis and configured to abrade the fouling from the surface, and a controller coupled to the chassis and in signal communication with the propulsion system and the first sensor. The controller is configured to receive a signal from the at least one sensor of the first type and control the propulsion system in response to the signal.

Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.

Abstract: Provided herein are pharmaceutical and cosmetic formulations and methods for regional adiposity reduction and treatment of body contour defects such as abdominal bulging; comprising an injectable formulation, said formulation comprising: an active ingredient that consists essentially of an adipose tissue-reducing amount of one or more lipophilic long-acting selective beta-2 adrenergic receptor agonists, or salts, solvates, or polymorphs thereof; and one or more subcutaneously acceptable inactive ingredients.

Abstract: A method for saving energy in locations using a plurality of luminaires situated in close proximity to each other, the method including providing each luminaire with a sensor for detecting presence of a person in proximity to the luminaire, a component for enabling passage of current through to the luminaire when the presence is detected and disabling the passage of the current through to the luminaire after a predetermined timeout, and a switch coupled between the component and the luminaire for enabling powering of the luminaire ON, wherein passage of power to each luminaire is enabled by the component when the presence is detected and the luminaire is powered ON by the switch.

Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.

Abstract: Disclosed herein are a system and a method for the production of hydrogen. The system advantageously combines an independent high temperature heat source with a solid oxide electrolyzer cell and a heat exchanger located between the cathode inlet and the cathode outlet. The heat exchanger is used to extract heat from the molecular components such as hydrogen derived from the electrolysis. A portion of the hydrogen generated in the solid oxide electrolyzer cell is recombined with steam and recycled to the solid oxide electrolyzer cell. The oxygen generated on the anode side is swept with compressed air and used to drive a gas turbine that is in operative communication with a generator. Electricity generated by the generator is used to drive the electrolysis in the solid oxide electrolyzer cell.

Abstract: A method of treating irritable bowel syndrome in a patient suffering therefrom comprising: administering an effective amount of a compound selected from compound 1, its metabolite 2 and pharmaceutically acceptable salts or esters thereof:

Abstract: Provided herein are lyophilized cake forms of fluticasone, salmeterol, or a pharmaceutically acceptable salt or a combination thereof which provides room temperature stability for an extended period of time. Upon reconstitution with an acceptable solvent (e.g., a carrier or diluent), the reconstituted pharmaceutical or cosmetic formulation provides a sterile, non-suspension form suitable for parenteral injectable administration, including subcutaneous injection.

Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.

Abstract: A method of treating irritable bowel syndrome in a patient suffering therefrom comprising: administering an effective amount of a compound selected from compound 1, its metabolite 2 and pharmaceutically acceptable salts or prodrugs thereof:

Abstract: A method of treating ulcerative colitis in a patient suffering therefrom comprising: administering an effective amount of a compound selected from compound 1, its metabolite 2 and pharmaceutically acceptable salts or esters thereof:

Abstract: A pharmaceutical composition comprising a compound of formula (1) in polymorphic crystalline Form A: together with a pharmaceutically acceptable carrier or excipient, wherein the compound of formula (1) is present in polymorphic Form A (see, e.g., FIG. 6) substantially free of other polymorphic forms.

Abstract: A system and method for operating a fuel cell, including reacting a fuel with an oxidant within the fuel cell to produce electricity and reaction products comprising steam. The fuel is fed through the fuel cell, wherein a concentration of the steam increases in the first direction through the fuel cell. The direction of fuel-flow through the fuel cell is altered or reversed upon satisfying a condition, thereby altering the concentration gradient of steam in the fuel cell and providing for removal of carbon deposition with the fuel cell. Such reversal of fuel flow may also provide an exhaust from the fuel cell that can regenerate an external or adjacent hydrocarbon reformer.

Abstract: An energy storage device is provided that includes a separator having a first surface and a second surface. The first surface defines at least a portion of a cathodic chamber, and the second surface defines an anodic chamber. The cathodic chamber includes an alkali metal halide that forms an ion that is capable of conducting through the separator. The anodic chamber has a volume that is filled with a consumable fluid. The amount of the consumable fluid is greater than 90 percent by volume of the anodic chamber volume. Furthermore, the consumable fluid is reactive with an ionic species of the alkali metal halide. A method of sealing the energy storage device is also provided.

Abstract: A method of making an electrode structure is provided. The method includes disposing an electrocatalytic material on an electrode, applying heat to the electrocatalytic material to form a volatile oxide of the electrocatalytic material, and applying a voltage to the electrode to reduce the volatile oxide to provide a number of nano-sized electrocatalytic particles on or proximate to a triple phase boundary, where the number of nano-sized electrocatalytic particles is greater on or proximate to the triple phase boundary than in an area that is not on or proximate to the triple phase boundary, and where the triple phase boundary is disposed on the electrode.

Abstract: A fuel cell assembly includes at least one fuel cell including at least two electrodes and an electrolyte. An interconnect structure includes at least one flow channel initially defined by a removable sacrificial material. A method of forming the fuel cell assembly includes the steps of providing the interconnect structure having at least one flow channel, depositing the sacrificial material into the flow channel, depositing an electrode or an electrode/electrolyte material upon the interconnect structure and the sacrificial material, and processing the fuel cell so as to remove the sacrificial material.

Abstract: An electrolyzer assembly comprises at least one electrolyzer cell including at least two electrodes and an electrolyte interposed therebetween. The electrolyzer assembly further comprises an interconnect structure in intimate contact with at least one of the two electrodes or the electrolyte. The interconnect structure includes at least one flow channel initially defined by a removable sacrificial material, wherein the interconnect structure is configured to provide support for the electrodes and the electrolyte.